- Q1 2024 Heron Therapeutics Inc Earnings Call TranscriptMay 07, 2024$2.73 (+1.11%)Earnings
- Q4 2023 Heron Therapeutics Inc Earnings Call TranscriptMar 12, 2024$2.44 (-1.81%)Earnings
- Q3 2023 Heron Therapeutics Inc Earnings Call TranscriptNov 14, 2023$0.60182 (+10.93%)Earnings
- Q2 2023 Heron Therapeutics Inc Earnings Call TranscriptAug 14, 2023$1.51 (-10.65%)Earnings
- Q1 2023 Heron Therapeutics Inc Earnings Call TranscriptMay 11, 2023$2.29 (-5.93%)Earnings
- Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 20, 2023
- Q4 2022 Heron Therapeutics Inc Earnings Call TranscriptMar 23, 2023$2.1 (+4.48%)Earnings
- Q3 2022 Heron Therapeutics Inc Earnings Call TranscriptNov 08, 2022$3.42Earnings
- Heron Therapeutics Inc Investor Call TranscriptSep 19, 2022
- Q2 2022 Heron Therapeutics Inc Earnings Call TranscriptAug 09, 2022$4.18 (+18.19%)Earnings
- Q1 2022 Heron Therapeutics Inc Earnings Call TranscriptMay 09, 2022$4.74Earnings
- Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Q4 2021 Heron Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$7.17Earnings
- Heron Therapeutics Inc Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF TranscriptDec 09, 2021
- Q3 2021 Heron Therapeutics Inc Earnings Call TranscriptNov 03, 2021$11.14Earnings
- Heron Therapeutics Inc to Host U.S. FDA Approval of ZYNRELEFâ„¢ - Conference Call TranscriptMay 13, 2021
- Heron Therapeutics Inc 2020 Conference Call TranscriptJun 29, 2020
- Heron Therapeutics Inc Annual Shareholders Meeting TranscriptJun 17, 2020
- Heron Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptOct 02, 2019
- Heron Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 14, 2019
- Heron Therapeutics Inc to discuss the Complete Response Letter - Conference Call TranscriptMay 01, 2019
Heron Therapeutics Inc Investor Call Transcript
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics conference call to discuss the FDA approval of APONVIE. As a reminder, this conference is being recorded. I would now like to turn the call over to David Szekeres, Executive Vice President, Chief Operating Officer. Please proceed.
Thank you, Mandeep. Good afternoon, everyone, and thank you for joining us. With me today from Heron are Barry Quart, Chief Executive Officer and Chairman; John Poyhonen, President and Chief Commercial Officer; Kimberly Manhard, Executive Vice President, Drug Development and Board Director; and Chris Storgard, Senior Vice President, Chief Medical Officer.
For those of you participating via conference call, the slides are made available via webcast and can also be accessed by going to the Investor Relations page of our website following conclusion of today's call. Barry will provide introductory remarks and offer context around the recent approval of APONVIE, the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)